Format

Send to

Choose Destination
Q J Nucl Med Mol Imaging. 2004 Dec;48(4):289-96.

Radioimmunotherapy with alpha-particle emitting radionuclides.

Author information

1
Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA. zalut001@mc.duke.edu

Abstract

An important consideration in the development of effective strategies for radioimmunotherapy is the nature of the radiation emitted by the radionuclide. Radionuclides decaying by the emission of alpha-particles offer the possibility of matching the cell specific reactivity of monoclonal antibodies with radiation with a range of only a few cell diameters. Furthermore, alpha-particles have important biological advantages compared with external beam radiation and beta-particles including a higher biological effectiveness, which is nearly independent of oxygen concentration, dose rate and cell cycle position. In this review, the clinical settings most likely to benefit from alpha-particle radioimmunotherapy will be discussed. The current status of preclinical and clinical research with antibodies labeled with 3 promising alpha-particle emitting radionuclides - (213)Bi, (225)Ac, and (211)At - also will be summarized.

PMID:
15640792
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Minerva Medica
Loading ...
Support Center